Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DMY004
MIFTS: 52

Demyelinating Disease

Categories: Neuronal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Demyelinating Disease

About this section

MalaCards integrated aliases for Demyelinating Disease:

Name: Demyelinating Disease 12 74 15
Demyelinating Diseases 54 43 71
Demyelinating Disorder 12

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3213
MeSH 43 D003711
NCIt 49 C34527
UMLS 71 C0011303
Sources

Summaries for Demyelinating Disease

About this section
Disease Ontology : 12 A neurodegenerative disease that is characterized by damage to the myelin sheath present around nerve axons.

MalaCards based summary : Demyelinating Disease, also known as demyelinating diseases, is related to neuromyelitis optica and balo concentric sclerosis. An important gene associated with Demyelinating Disease is MBP (Myelin Basic Protein), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and spinal cord, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : 74 A demyelinating disease is any disease of the nervous system in which the myelin sheath of neurons is... more...

Sources

Related Diseases for Demyelinating Disease

About this section

Diseases related to Demyelinating Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 694)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 33.7 MOG MBP IL7R IL1B IL17A HLA-DRB1
2 balo concentric sclerosis 33.6 MOG MBP IFNB1 AQP4
3 multiple sclerosis 33.1 TNFRSF1A TNF PTPRC PLP1 MPZ MOG
4 acute transverse myelitis 32.3 IL10 AQP4
5 allergic encephalomyelitis 32.3 PLP1 MOG MBP CCL2
6 transverse myelitis 31.8 TNF MBP IL17A IL10 AQP4
7 optic neuritis 31.8 TNF PLP1 MPZ MOG MBP IL1B
8 neuritis 31.7 TNF MPZ MOG MBP IL1B IL10
9 acute disseminated encephalomyelitis 31.7 MPZ MOG MBP IL1B IL10 IFNB1
10 myelitis 31.6 TNFRSF1A TNF MOG MBP IL17A IL10
11 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.6 IL17A IL10 IFNG
12 progressive multifocal leukoencephalopathy 31.6 TNF MBP IFNB1 CCR6
13 guillain-barre syndrome 31.6 TNFRSF1A TNF MPZ MOG MBP HLA-DRB1
14 polyneuropathy 31.4 TNF MPZ MBP IL1B
15 autoimmune disease 31.4 TNFRSF1A TNF PLP1 MOG MBP IL1B
16 encephalitis 31.4 TNF PTPRC MOG IL1B IL10 IFNB1
17 measles 31.4 TNF IL1B IFNG IFNB1 HLA-DRB1
18 vasculitis 31.3 TNF IL17A IL10 CCL2
19 chronic inflammatory demyelinating polyradiculoneuropathy 31.2 MPZ MBP IL17A IL10 IFNG IFNB1
20 subacute sclerosing panencephalitis 31.2 TNF MOG MBP IL10 IFNG
21 myasthenia gravis 31.1 TNF PLP1 MBP IL10 IFNG
22 spondyloarthropathy 1 31.0 TNFRSF1A TNF IL17A CCR6
23 quadriplegia 31.0 PLP1 MOG MBP CCR6
24 polyradiculoneuropathy 31.0 TNFRSF1A MPZ MBP IL17A IL10 IFNG
25 spondylitis 30.9 TNF IL17A IL10 IFNG CCR6
26 optic nerve disease 30.9 TNF MOG MBP IL1B IL17A IFNB1
27 relapsing-remitting multiple sclerosis 30.9 TNF PLP1 MOG MBP IL7R IL1B
28 allergic hypersensitivity disease 30.9 TNF IL17A IL10 IFNG CCR6
29 coronavirus infectious disease 30.9 TNF IFNB1 CCR6
30 nervous system disease 30.9 TNF MOG IL1B IFNG CCR6
31 proteasome-associated autoinflammatory syndrome 1 30.8 TNF IL1B IL17A IL10 IFNG CCL2
32 spinal cord injury 30.8 TNF CSPG4 AQP4
33 pustulosis of palm and sole 30.8 TNF IL17A CCR6
34 mumps 30.8 TNFRSF1A TNF IL1B IL10 IFNG IFNB1
35 uveitis 30.8 TNFRSF1A TNF IL1B IL17A IL10 IFNG
36 acute retrobulbar neuritis 30.8 MBP AQP4
37 acquired immunodeficiency syndrome 30.8 TNFRSF1A TNF MBP IL1B IL10 IFNG
38 intracranial hypertension 30.8 TNF IL1B AQP4
39 inflammatory bowel disease 30.7 TNFRSF1A TNF PTPRC IL7R IL1B IL17A
40 graft-versus-host disease 30.7 TNF IL1B IL10 IFNG HLA-DRB1
41 primary progressive multiple sclerosis 30.7 TNF PLP1 MOG MBP IL7R IL10
42 psoriatic arthritis 30.7 TNFRSF1A TNF IL1B IL17A IL10 IFNG
43 internuclear ophthalmoplegia 30.7 MOG MBP IFNB1 AQP4
44 juvenile rheumatoid arthritis 30.7 TNFRSF1A TNF IL1B IL10 IFNG HLA-DRB1
45 herpes zoster 30.7 TNF IL10 IFNG HLA-DRB1 CCR6
46 hydrocephalus 30.7 TNF NTF3 MBP IL10 IFNG AQP4
47 metachromatic leukodystrophy 30.6 PTPRC PLP1 MPZ MBP
48 rubella 30.6 TNF MOG IL1B IL10 IFNG IFNB1
49 lyme disease 30.6 TNF IL1B IL17A IFNB1 HLA-DRB1
50 viral encephalitis 30.6 TNF MOG MBP IL1B IL10 IFNB1

Graphical network of the top 20 diseases related to Demyelinating Disease:



Diseases related to Demyelinating Disease
Sources

Symptoms & Phenotypes for Demyelinating Disease

About this section

GenomeRNAi Phenotypes related to Demyelinating Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 ABCD1 CCL2 CCR6 IL17A MOG NTF3

MGI Mouse Phenotypes related to Demyelinating Disease:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 ABCD1 AQP4 CCR6 CSPG4 IFNB1 IFNG
2 immune system MP:0005387 10.39 ABCD1 AQP4 CCL2 CCR6 CSPG4 IFNB1
3 homeostasis/metabolism MP:0005376 10.36 ABCD1 AQP4 CCR6 CSPG4 IFNB1 IFNG
4 growth/size/body region MP:0005378 10.34 AQP4 CSPG4 IFNG IL10 IL17A IL1B
5 nervous system MP:0003631 10.27 ABCD1 AQP4 CCR6 CSPG4 IFNB1 IFNG
6 neoplasm MP:0002006 10.01 IFNB1 IFNG IL10 IL1B IL7R PTPRC
7 no phenotypic analysis MP:0003012 9.97 AQP4 CSPG4 IFNB1 IFNG IL10 IL17A
8 normal MP:0002873 9.96 ABCD1 CCR6 CSPG4 IFNB1 IFNG IL10
9 respiratory system MP:0005388 9.81 AQP4 IFNG IL10 IL17A MPZ NTF3
10 skeleton MP:0005390 9.65 IFNB1 IFNG IL10 IL17A IL1B MPZ
11 vision/eye MP:0005391 9.32 ABCD1 AQP4 IFNG IL10 MBP MOG
Sources

Drugs & Therapeutics for Demyelinating Disease

About this section

Drugs for Demyelinating Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
4
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
5
rituximab Approved Phase 4 174722-31-7 10201696
6
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
7
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
8 Antitubercular Agents Phase 4
9 Anti-Bacterial Agents Phase 4
10 Antibiotics, Antitubercular Phase 4
11 Retinol palmitate Phase 4
12 retinol Phase 4
13 Analgesics Phase 4
14 Calcium, Dietary Phase 4
15 Trace Elements Phase 4
16 Vitamins Phase 4
17 Nutrients Phase 4
18 Micronutrients Phase 4
19 Vasoconstrictor Agents Phase 4
20 Antineoplastic Agents, Immunological Phase 4
21 Adrenocorticotropic Hormone Phase 4
22 Melanocyte-Stimulating Hormones Phase 4
23 beta-Endorphin Phase 4
24
Calcium Nutraceutical Phase 4 7440-70-2 271
25
Simvastatin Approved Phase 3 79902-63-9 54454
26
alemtuzumab Approved, Investigational Phase 3 216503-57-0
27
Baclofen Approved Phase 3 1134-47-0 2284
28
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
29
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
30
Mesna Approved, Investigational Phase 3 3375-50-6 598
31
Lenograstim Approved, Investigational Phase 3 135968-09-1
32
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
33 Pharmaceutical Solutions Phase 3
34 Antineoplastic Agents, Hormonal Phase 3
35 Antibodies Phase 3
36 Immunoglobulins Phase 3
37 Immunoglobulins, Intravenous Phase 3
38 Rho(D) Immune Globulin Phase 3
39 gamma-Globulins Phase 3
40 polysaccharide-K Phase 3
41 Alkylating Agents Phase 3
42 Immunoglobulin G Phase 3
43 Thymoglobulin Phase 3
44 Immunoglobulin A Phase 3
45 Immunoglobulin M Phase 3
46
Amiloride Approved Phase 2 2016-88-8, 2609-46-3 16231
47
Hydrochlorothiazide Approved, Vet_approved Phase 2 58-93-5 3639
48
Rifampicin Approved Phase 2 13292-46-1 5381226 5458213
49
Azithromycin Approved Phase 2 83905-01-5 447043 55185
50
Atorvastatin Approved Phase 2 134523-00-5 60823

Interventional clinical trials:

(show top 50) (show all 131)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
3 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
4 The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients Unknown status NCT01407211 Phase 4
5 Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses Unknown status NCT03021317 Phase 4 ACTHar
6 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
7 Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)
8 Pilot Open-Label Clinical Trial to Test Efficacy and Safety of Combination of Clobex® Spray With Excimer Laser Therapy [Photomedex XTRAC ® Velocity] in the Treatment of Generalized Plaque Psoriasis Followed by Maintenance With Topical Vectical® Ointment Completed NCT01012713 Phase 4 Clobex Spray;Vectical Ointment
9 Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE): a Prospective, Multicenter, Open-label, Follow-up Clinical Trial Active, not recruiting NCT04256252 Phase 4 Rituximab
10 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4 ACTHAR;ACTHAR;ACTHAR;ACTHAR
11 An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
12 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
13 Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial Unknown status NCT00261326 Phase 3 simvastatin;placebo
14 A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis Unknown status NCT00242268 Phase 3 Simvastatin
15 Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients Completed NCT01307332 Phase 3 MabCampath-1h
16 A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis Completed NCT03290131 Phase 3 Arbaclofen;Placebo
17 Randomized Clinical Trial of Plasma Exchanges Versus Sham Plasma Exchanges in Disabling Multiple Sclerosis Acute Relapses Refractory to Steroid Treatment Completed NCT01442233 Phase 3
18 Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
19 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Active, not recruiting NCT02549170 Phase 3
20 Maximizing Outcome of Multiple Sclerosis Transplantation: "MOST" Trial Active, not recruiting NCT03342638 Phase 3 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF
21 Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
22 An Open Label Study of the Effects of Eculizumab in CD59 Deficiency Unknown status NCT01579838 Phase 1, Phase 2 Eculizumab
23 A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
24 Pilot Trial of Interferon Beta-1a in Alzheimer's Disease Completed NCT01075763 Phase 2 Interferon beta-1a;Placebo
25 Study of Melatonin in Treatment of Fatigue in Multiple Sclerosis Completed NCT01718678 Phase 2 Melatonin;Placebo
26 Study of Ginseng in Treatment of Fatigue in Multiple Sclerosis Completed NCT01712373 Phase 2 Ginseng;Placebo
27 Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment Completed NCT01056471 Phase 1, Phase 2
28 Effects of Melatonin on Clinical and Neuroimaging Indices of Relapsing-Remitting Multiple Sclerosis Patients Completed NCT01279876 Phase 2 Melatonin
29 A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201 Completed NCT02657915 Phase 2 Placebo;BIIB033 100mg/Kg
30 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
31 Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis Completed NCT00043264 Phase 2 Rifampin;Azithromycin
32 Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis Completed NCT02495766 Phase 1, Phase 2 XCEL-MC-ALPHA;Placebo
33 Assessment of Chronic GBS Improvement With Use of 4-AP Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
34 Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis Completed NCT01305837 Phase 2 methylprednisolone
35 Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
36 SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study ("SWABIMS Follow Up-study") Completed NCT01111656 Phase 2 Interferon beta-1b group;Interferon beta-1b/Atorvastatin group
37 Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis Completed NCT02493049 Phase 2 Domperidone
38 Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis. Completed NCT00942591 Phase 2 Interferon beta 1b;Atorvastatin
39 Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis Completed NCT02035514 Phase 1, Phase 2
40 Effect of the Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (IL-2R-Alpha; Zenapax(Registered Trademark)) on Inflammatory Activity in the CNS in MS in a Baseline-to-Treatment, Cross-Over, MRI-Controlled Single Center Phase I/II Trial Completed NCT00001934 Phase 2 Zenapax
41 Zenapax (Daclizumab) Admin to Pts With Multiple Sclerosis (ZAP MS): Effect of Intravenously Admin Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (Daclizumab) on Inflammatory Activity in the Central Nervous System Completed NCT00071838 Phase 2 Daclizumab
42 Randomized, Comparative, Double Blind Controlled Phase II Clinical Trial, to Evaluate the Efficacy of ApE in Patients With Multiple Sclerosis (MS). Completed NCT02280876 Phase 1, Phase 2 1 - Andrographis paniculata p/st extract;2 - Excipients
43 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis Recruiting NCT02521311 Phase 2 Clemastine;Placebo
44 A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis Recruiting NCT03536559 Phase 2 CNM-Au8;Placebo
45 Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study Active, not recruiting NCT00273364 Phase 2 Standard treatment with a conventional drug
46 Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders: a Prospective, Multicenter, Single-blind, Randomized Controlled Clinical Trial Not yet recruiting NCT04064944 Phase 2
47 A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma Not yet recruiting NCT04026568 Phase 1, Phase 2 4-Aminopyridine;Placebo oral tablet
48 A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis Terminated NCT01874340 Phase 2 Placebo;AIN457
49 Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis Withdrawn NCT00296205 Phase 2 Cyclophosphamide
50 Evaluation of the Tolerance and Efficiency of a Combined Oral Therapy With Lithium and GTA in Patients With Canavan Disease Withdrawn NCT00657748 Phase 2 Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)

Search NIH Clinical Center for Demyelinating Disease

Cochrane evidence based reviews: demyelinating diseases

Sources

Genetic Tests for Demyelinating Disease

About this section
Sources

Anatomical Context for Demyelinating Disease

About this section

MalaCards organs/tissues related to Demyelinating Disease:

40
Brain, T Cells, Spinal Cord, B Cells, Bone, Testes, Bone Marrow
Sources

Publications for Demyelinating Disease

About this section

Articles related to Demyelinating Disease:

(show top 50) (show all 6594)
# Title Authors PMID Year
1
STAT1/IRF-1 signaling pathway mediates the injurious effect of interferon-gamma on oligodendrocyte progenitor cells. 61 54
19606498 2010
2
Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. 54 61
20033986 2009
3
Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. 61 54
20008665 2009
4
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. 61 54
19938104 2009
5
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. 61 54
19892975 2009
6
[What I have learned and accomplished through research on multiple sclerosis (MS)]. 54 61
20030191 2009
7
Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. 61 54
19229993 2009
8
Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. 54 61
19465451 2009
9
The innate immune response affects the development of the autoimmune response in Theiler's virus-induced demyelinating disease. 61 54
19380818 2009
10
Assessment of citrullinated myelin by 1H-MR spectroscopy in early-onset multiple sclerosis. 54 61
19147724 2009
11
[Neuromyelitis optica and anti-aquaporin 4 antibody--distinct from multiple sclerosis]. 54 61
19363997 2009
12
Interactions between Schwann cells and macrophages in injury and inherited demyelinating disease. 61 54
18803324 2008
13
Polarity development in oligodendrocytes: sorting and trafficking of myelin components. 54 61
18172773 2008
14
[Neuromyelitis optica and anti-aquaporin 4 antibody--an overview]. 61 54
18516975 2008
15
Water movements in the brain: role of aquaporins. 54 61
18054802 2008
16
Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response. 54 61
18484192 2008
17
Cleavage of myelin associated glycoprotein by matrix metalloproteinases. 61 54
18063113 2008
18
[Neuromyelitis optica]. 61 54
17934711 2007
19
The complex etiology of multiple sclerosis. 54 61
17537409 2007
20
[TNF-alpha inhibitors and demyelinating disease]. 54 61
18062640 2007
21
Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. 61 54
17456525 2007
22
Neuromyelitis optica. 61 54
17495617 2007
23
Crohn's disease: a review of current treatment with a focus on biologics. 61 54
18034589 2007
24
Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. 61 54
17294606 2007
25
No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab. 54 61
16606644 2006
26
Complex alternative splicing of the myelin oligodendrocyte glycoprotein gene is unique to human and non-human primates. 61 54
16903876 2006
27
Interleukin 23 in acute inflammatory demyelination of the peripheral nerve. 54 61
16769867 2006
28
Long term safety of etanercept in elderly subjects with rheumatic diseases. 54 61
16150792 2006
29
Statistical diffusion tensor histology reveals regional dysmyelination effects in the shiverer mouse mutant. 54 61
16213163 2006
30
Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. 61 54
16227104 2005
31
Citrullination of central nervous system proteins during the development of experimental autoimmune encephalomyelitis. 61 54
15844172 2005
32
NG2-positive cells in CNS function and the pathological role of antibodies against NG2 in demyelinating diseases. 54 61
15949494 2005
33
Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. 54 61
15809314 2005
34
GALC transduction leads to morphological improvement of the twitcher oligodendrocytes in vivo. 61 54
15781194 2005
35
The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications. 54 61
16268663 2005
36
Astroglial-derived lymphotoxin-alpha exacerbates inflammation and demyelination, but not remyelination. 54 61
15382206 2005
37
The 14-3-3 protein in multiple sclerosis: a marker of disease severity. 54 61
15471360 2004
38
A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. 54 61
15370396 2004
39
Demyelination and inhibition of tumor necrosis factor (TNF). 54 61
15552527 2004
40
Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. 61 54
15268666 2004
41
Increased susceptibility to experimental autoimmune neuritis after upregulation of the autoreactive T cell response to peripheral myelin antigen in apolipoprotein E-deficient mice. 61 54
14989598 2004
42
Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. 54 61
15219899 2004
43
Safety of tumour necrosis factor-alpha antagonists. 54 61
15061685 2004
44
Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. 61 54
15058523 2004
45
A combinatorial network of evolutionarily conserved myelin basic protein regulatory sequences confers distinct glial-specific phenotypes. 61 54
14614079 2003
46
Transient exposure to FGF2 enhances myelination in embryonic brain cell cocultures. 61 54
12710930 2003
47
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. 61 54
12620653 2003
48
Decreased frequency of the tumor necrosis factor alpha -308 allele in Serbian patients with multiple sclerosis. 54 61
12824709 2003
49
TNFalpha downregulates PPARdelta expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. 61 54
12465041 2003
50
Multiple sclerosis candidate autoantigens except myelin oligodendrocyte glycoprotein are transcribed in human thymus. 61 54
12355425 2002
Sources

Variations for Demyelinating Disease

About this section
Sources

Expression for Demyelinating Disease

About this section
Search GEO for disease gene expression data for Demyelinating Disease.
Sources

Pathways for Demyelinating Disease

About this section

Pathways related to Demyelinating Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.07 TNFRSF1A TNF PTPRC IL7R IL1B IL17A
2
ERK Signaling 63
Show member pathways
 13.85 TNFRSF1A TNF NTF3 IL7R IL1B IL17A
3
PEDF Induced Signaling 63
Show member pathways
 13.73 TNFRSF1A TNF IL7R IL1B IL17A IL10
4
TGF-Beta Pathway 63
Show member pathways
 13.6 TNFRSF1A TNF NTF3 IL7R IL1B IL17A
5
Akt Signaling 63
Show member pathways
 13.47 TNFRSF1A TNF NTF3 IL7R IL1B IL17A
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.33 TNFRSF1A TNF IL7R IL1B IL17A IL10
7
PAK Pathway 63
Show member pathways
 13.24 TNFRSF1A TNF PTPRC NTF3 IL7R IL1B
8
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.12 TNFRSF1A TNF IL1B IL10 IFNG IFNB1
9
Allograft rejection 1 36
Show member pathways
 12.91 TNF IL1B IL17A IL10 IFNG HLA-DRB1
10
Measles 36
Show member pathways
 12.88 TNFRSF1A TNF IL1B IFNG IFNB1 HLA-DRB1
11
Herpes simplex virus 1 infection 36
12.85 TNFRSF1A TNF IL1B IFNG IFNB1 HLA-DRB1
12
Immune response NFAT in immune response 22
Show member pathways
 12.7 TNFRSF1A TNF PTPRC IL10 IFNG HLA-DRB1
13
T cell receptor signaling pathway 36
Show member pathways
 12.67 TNF PTPRC IL1B IL17A IL10 IFNG
14
Th17 cell differentiation 36
Show member pathways
 12.67 TNF IL1B IL17A IL10 IFNG HLA-DRB1
15
Immune response IL-23 signaling pathway 22
Show member pathways
 12.65 TNF IL1B IL17A IL10 IFNG CCL2
16
JAK-STAT signaling pathway 36
Show member pathways
 12.5 PTPRC IL7R IL10 IFNG IFNB1
17
NF-kappaB Signaling 4
12.48 TNFRSF1A TNF PTPRC IL1B IL17A IL10
18
Shigellosis 36
12.42 TNFRSF1A TNF IL1B IFNB1
19
IL-17 Family Signaling Pathways 64
Show member pathways
 12.41 TNF IL1B IL17A IFNG CCL2
20
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.4 TNFRSF1A TNF IL10 CCR6 CCL2
21
Folate Metabolism 1
Show member pathways
 12.36 TNF IL1B IFNG CCL2
22
Salmonella infection (KEGG) 36
12.34 TNFRSF1A TNF PTPRC IL1B
23
NOD-like receptor signaling pathway 36
12.28 TNF IL1B IFNB1 CCL2
24
Necroptosis 36
Show member pathways
 12.27 TNFRSF1A TNF IL1B IFNG IFNB1
25
Toxoplasmosis 36
Show member pathways
 12.26 TNFRSF1A TNF IL1B IL10 IFNG HLA-DRB1
26
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.25 TNF NTF3 IL1B IL17A IL10 IFNG
27
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.24 TNF PLP1 IL1B IL10 AQP4
28
Bacterial infections in CF airways 22
Show member pathways
 12.23 TNF IL1B IFNG IFNB1
29
Fluid shear stress and atherosclerosis 36
12.16 TNFRSF1A TNF IL1B IFNG CCL2
30
Tuberculosis 36
12.12 TNFRSF1A TNF IL1B IL10 IFNG IFNB1
31
Osteoclast differentiation 36
12.11 TNFRSF1A TNF IL1B IFNG IFNB1
32
Yersinia infection 36
12.08 TNF IL1B IL10 IFNB1 CCL2
33
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.05 TNF PTPRC IL7R IL10 IFNG
34
Interleukin-4 and 13 signaling 65
12.04 TNF IL1B IL17A IL10 CCL2
35
TNF signaling pathway 36
12.02 TNFRSF1A TNF IL1B IFNB1 CCL2
36
Amoebiasis 36
12 TNF IL1B IL10 IFNG
37
Hematopoietic cell lineage 36
11.98 TNF IL7R IL1B HLA-DRB1
38
IL27-mediated signaling events 1
Show member pathways
 11.97 TNF IL1B IL17A IL10 IFNG
39
Spinal Cord Injury 1
11.88 TNF MBP IL1B IFNG CSPG4 CCL2
40
Rheumatoid arthritis 36
11.85 TNF IL1B IL17A IFNG HLA-DRB1 CCL2
41
TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.82 TNFRSF1A TNF NTF3
42
Neural Stem Cells and Lineage-specific Markers 64
11.8 NTF3 MOG CSPG4
43
Pertussis 36
11.78 TNF IL1B IL10
44
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.74 TNFRSF1A TNF IL1B IFNG
45
Lung fibrosis 1
11.7 TNF IL1B CCL2
46
Photodynamic therapy-induced AP-1 survival signaling. 1
11.6 TNFRSF1A TNF IFNG
47
Cellular Transformation by HTLV1 63
Show member pathways
 11.6 TNFRSF1A TNF IFNG
48
MSP-RON Signaling 63
11.6 TNF IL1B IFNG CCL2
49
Aryl Hydrocarbon Receptor Pathway 1
11.57 TNF IL1B IFNG
50
Dendritic Cells Developmental Lineage Pathway 64
11.57 TNF PTPRC IL7R IL1B IL10 IFNG
Sources

GO Terms for Demyelinating Disease

About this section

Cellular components related to Demyelinating Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.97 TNFRSF1A TNF PTPRC MPZ HLA-DRB1 CSPG4
2 extracellular space GO:0005615 9.96 TNFRSF1A TNF NTF3 IL1B IL17A IL10
3 extracellular region GO:0005576 9.73 TNFRSF1A TNF NTF3 IL7R IL1B IL17A
4 cell surface GO:0009986 9.7 TNFRSF1A TNF PTPRC MBP HLA-DRB1 CSPG4
5 myelin sheath GO:0043209 9.5 PLP1 MPZ MBP
6 external side of plasma membrane GO:0009897 9.23 TNF PTPRC MOG IL7R IL17A HLA-DRB1

Biological processes related to Demyelinating Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 TNFRSF1A NTF3 IL7R IL1B IL10 HLA-DRB1
2 positive regulation of gene expression GO:0010628 10.11 TNF PLP1 IL7R IL1B IFNG
3 inflammatory response GO:0006954 10.02 TNFRSF1A TNF PLP1 IL1B IL17A CCL2
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 10 TNF PTPRC HLA-DRB1 CCL2
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.98 TNFRSF1A TNF IL1B HLA-DRB1
6 positive regulation of protein phosphorylation GO:0001934 9.98 TNF IL1B IFNG HLA-DRB1
7 cellular response to lipopolysaccharide GO:0071222 9.97 TNF IL1B IL10 CCL2
8 cell surface receptor signaling pathway GO:0007166 9.95 TNFRSF1A PTPRC IL7R IFNG IFNB1 CCL2
9 B cell differentiation GO:0030183 9.89 PTPRC IL10 IFNB1
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 TNFRSF1A TNF IFNG
11 regulation of insulin secretion GO:0050796 9.87 TNF IL1B IFNG
12 cellular response to organic cyclic compound GO:0071407 9.87 TNF IL1B CCL2
13 positive regulation of inflammatory response GO:0050729 9.86 TNFRSF1A TNF IL1B IFNG
14 myelination GO:0042552 9.85 PLP1 MPZ MBP
15 activation of MAPK activity GO:0000187 9.83 TNF PTPRC NTF3 IL1B CSPG4
16 positive regulation of phagocytosis GO:0050766 9.81 TNF IL1B IFNG
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.81 TNF IL1B IFNG
18 protein kinase B signaling GO:0043491 9.8 TNF IL1B CCL2
19 cytokine-mediated signaling pathway GO:0019221 9.8 TNFRSF1A TNF IL1B IL17A IL10 IFNB1
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.79 TNF IL1B CCL2
21 positive regulation of cytokine secretion GO:0050715 9.77 TNF IL10 IFNG
22 positive regulation of osteoclast differentiation GO:0045672 9.74 TNF IL17A IFNG
23 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.71 MBP IL10
24 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
25 astrocyte activation GO:0048143 9.71 TNF IL1B IFNG
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 IL10 IFNG
27 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 TNF IL1B IFNG
28 endothelial cell apoptotic process GO:0072577 9.69 TNF IL10
29 death-inducing signaling complex assembly GO:0071550 9.69 TNFRSF1A TNF
30 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 TNF IL1B IL10
31 positive regulation of NMDA glutamate receptor activity GO:1904783 9.68 IFNG CCL2
32 axon ensheathment GO:0008366 9.68 PLP1 MBP
33 negative regulation of cytokine production involved in immune response GO:0002719 9.67 TNF IL10
34 positive regulation of chemokine biosynthetic process GO:0045080 9.67 TNF IL1B IFNG
35 B cell proliferation GO:0042100 9.67 PTPRC IL7R IL10 IFNB1
36 negative regulation of T cell mediated cytotoxicity GO:0001915 9.66 PTPRC IL7R
37 positive regulation of interleukin-23 production GO:0032747 9.65 IL17A IFNG
38 positive regulation of fever generation GO:0031622 9.65 TNF IL1B
39 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.65 TNF PTPRC
40 negative regulation of cytokine secretion involved in immune response GO:0002740 9.64 TNF IL10
41 sequestering of triglyceride GO:0030730 9.63 TNF IL1B
42 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.63 TNF IL17A IFNG
43 receptor biosynthetic process GO:0032800 9.61 TNF IL10
44 positive regulation of T cell mediated immunity GO:0002711 9.61 PTPRC IL1B
45 DN2 thymocyte differentiation GO:1904155 9.59 PTPRC CCR6
46 positive regulation of vitamin D biosynthetic process GO:0060557 9.58 TNF IFNG
47 positive regulation of nitrogen compound metabolic process GO:0051173 9.58 TNF IFNG
48 regulation of establishment of endothelial barrier GO:1903140 9.58 TNFRSF1A TNF IL1B
49 humoral immune response GO:0006959 9.55 TNF IFNG IFNB1 CCR6 CCL2
50 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.5 TNF IL1B IFNG

Molecular functions related to Demyelinating Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 TNF IL1B IL17A IL10 IFNG IFNB1
2 structural constituent of myelin sheath GO:0019911 8.96 PLP1 MBP
Sources

Sources for Demyelinating Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....